Quarterly report · Q3
4570.TEDINET S100Q59N
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥555m | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥648m | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥448m | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥19m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | −¥137m | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | −¥68m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥243m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥233m | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥70m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥237m | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥76m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥259m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥244m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥76m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | −¥244m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥1.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥1.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.7bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥338m | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥337m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥394m | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥508m | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-8.2 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.41 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.14 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.7% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 25
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥11m |
| jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥61m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥92m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥555m |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥555m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥19m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | ¥560,000 |
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥12m |
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥12m |
| jpcrp040300-q3r_E00986-000Cosmeticsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | −¥9m |
| jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segment | segment profit | 2021-04-01 → 2021-12-31 | −¥78m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥440m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥436m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥3m |
| jpcrp040300-q3r_E00986-000Immunity Relatedreportable segment | segment profit | 2021-04-01 → 2021-12-31 | −¥51m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥451m |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥448m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥3m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | −¥137m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 314
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |